Peptide-modified bioresponsive chondroitin sulfate micelles for targeted doxorubicin delivery in triple-negative breast cancer

Colloids and Surfaces B Biointerfaces, Journal Year: 2023, Volume and Issue: 227, P. 113381 - 113381

Published: May 26, 2023

Language: Английский

---

Metastatic Breast Cancer: Review of Emerging Nanotherapeutics

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 2906 - 2906

Published: May 25, 2023

Metastases of breast cancer (BC) are often referred to as stage IV due their severity and high rate mortality. The median survival time patients with metastatic BC is reduced 3 years. Currently, the treatment regimens for similar primary therapeutics limited conventional chemotherapy, immunotherapy, radiotherapy, surgery. However, shows organ-specific complex tumor cell heterogeneity, plasticity, a distinct microenvironment, leading therapeutic failure. This issue can be successfully addressed by combining current therapies nanotechnology. applications nanotherapeutics both treatments developing rapidly, new ideas technologies being discovered. Several recent reviews covered advancement BC, while also discussing certain aspects BC. review provides comprehensive details on future prospects designed treatment, in context pathological state disease. Furthermore, possible combinations nanotechnology discussed, potential transitions clinical settings explored.

Language: Английский

---

Suppressing Wnt signaling of the blood‒tumor barrier to intensify drug delivery and inhibit lipogenesis of brain metastases

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(6), P. 2716 - 2731

Published: March 21, 2024

Lipogenesis is often highly upregulated in breast cancer brain metastases to adapt intracranial low lipid microenvironments. Lipase inhibitors hold therapeutic potential but their intra-tumoral distribution blocked by the blood‒tumor barrier (BTB). BTB activates its Wnt signaling maintain properties,

Language: Английский

---

Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood–tumor barrier for boosted brain tumor therapy

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 369, P. 458 - 474

Published: April 6, 2024

Language: Английский

---

Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends

International Journal of Cancer, Journal Year: 2023, Volume and Issue: 153(6), P. 1118 - 1129

Published: April 25, 2023

Abstract Breast cancer brain metastasis (BCBM) is rapidly becoming an impediment to continuing survival gains seen in breast patients. Drug delivery across the blood‐brain barrier main issue hindering systemic therapy against BCBM. This review details recent advances nanoparticle (NP) drug systems target Their primary benefits are: enhanced circulating and intra‐BCBM biodistribution, BCBM targeting through NP functionalization, opportunities for gene manipulation their theragnostic applications. Multiple NPs have been synthesized deliver therapeutic HER2 blockade, which particularly important given HER2‐positive cancer's tendency form Finally, we clinical context NP‐based therapeutics investigated While a breakthrough improving patient outcomes remain awaited, these trials represent positive steps changing attitude towards as treatable illness. Although multiple challenges translation of BCBM‐directed therapies, ongoing research field offers promising avenues novel this devastating disease.

Language: Английский

---

Receptor-Assisted Nanotherapeutics for Overcoming the Blood–Brain Barrier

Molecular Neurobiology, Journal Year: 2024, Volume and Issue: unknown

Published: April 1, 2024

Abstract Blood–brain barrier (BBB) is a distinguishing checkpoint that segregates peripheral organs from neural compartment. It protects the central nervous system harmful ambush of antigens and pathogens. Owing to such explicit selectivity, BBB hinders passage various neuroprotective drug molecules escalates into poor attainability agents towards brain. However, few can surpass gain access in brain parenchyma by exploiting surface transporters receptors. For successful development brain-targeted therapy, understanding receptors crucial. This review focuses on transporter receptor–based mechanistic pathway be manoeuvred for better comprehension reciprocity nanotechnological vehicle delivery. Nanotechnology has emerged as one expedient noninvasive approaches targeting via manipulating hurdle BBB. Various nanovehicles are being reported delivery nanoparticles, nanocrystals, nanoemulsion, nanolipid carriers, liposomes other nanovesicles. Nanotechnology-aided strategic approach circumvent without altering inherent nature

Language: Английский

---

Brain-tumor-seeking and serpin-inhibiting outer membrane vesicles restore plasmin-mediated attacks against brain metastases

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 375, P. 116 - 126

Published: Sept. 6, 2024

Language: Английский

---

DH5α Outer Membrane‐Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94

Small, Journal Year: 2023, Volume and Issue: 19(35)

Published: April 27, 2023

Receptor-mediated vesicular transport has been extensively developed to penetrate the blood-brain barrier (BBB) and emerged as a class of powerful brain-targeting delivery technologies. However, commonly used BBB receptors such transferrin receptor low-density lipoprotein receptor-related protein 1, are also expressed in normal brain parenchymal cells can cause drug distribution tissues subsequent neuroinflammation cognitive impairment. Here, endoplasmic reticulum residing GRP94 is found upregulated relocated cell membrane both endothelial metastatic breast cancer (BMBCCs) by preclinical clinical investigations. Inspired that Escherichia coli penetrates via binding its outer proteins with GRP94, avirulent DH5α protein-coated nanocapsules (Omp@NCs) cross BBB, avert cells, target BMBCCs recognizing GRP94. Embelin (EMB)-loaded Omp@EMB specifically reduce neuroserpin BMBCCs, which inhibits vascular cooption growth induces apoptosis restoring plasmin. plus anti-angiogenic therapy prolongs survival mice metastases. This platform holds translational potential maximize therapeutic effects on GRP94-positive diseases.

Language: Английский

---

GRP94 mediates blood-brain barrier permeation and substantia nigra-specific drug distribution in Parkinson’s disease

Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: unknown, P. 114585 - 114585

Published: Feb. 1, 2025

Language: Английский

---

Biological profile of breast cancer brain metastasis

Acta Neuropathologica Communications, Journal Year: 2025, Volume and Issue: 13(1)

Published: April 19, 2025

Breast cancer is one of the leading causes death worldwide. The aggressive behaviour breast tumor results from their metastasis. Notably, brain tissue common regions metastasis, thereby reducing overall survival patients. Moreover, metastatic tumors demonstrate poor response or resistance to therapies. In addition, metastasis provides prognosis Therefore, it importance understand mechanisms in Both cell lines and animal models have been developed for evaluation different microenvironment components other factors such as lymphocytes astrocytes can affect cells disrupt blood-brain barrier (BBB) during into brain, developing blood-tumor enhance carcinogenesis. be increased by dysregulation chemokines, STAT3, Wnt, Notch PI3K/Akt. On hand, effective therapeutics introduction nanoparticles. disruption BBB ultrasound increase entrance bioactive compounds tissue. order improve specificity selectivity, nanoparticles delivery crossing over suppress

Language: Английский

---